GeneDx Holdings (WGS) AI Stock Analysis

• Market Cap: $3.02B
• Dividend Yield: N/A
• Average Volume (3M): 445.20K
• Price to Earnings (P/E): 1812.3
• Beta (1Y): 1.24
• Revenue Growth: 50.50%
• EPS Growth: N/A
• Country: US
• Employees: 1,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.49
• Shares Outstanding: 28,904,590
• 10 Day Avg. Volume: 598,491
• 30 Day Avg. Volume: 445,204
• PEG Ratio: 0.54
• Price to Book (P/B): 8.43
• Price to Sales (P/S): 6.77
• P/FCF Ratio: -60.81
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 7.76
• Enterprise Value/Gross Profit: 11.14
• Enterprise Value/Ebitda: 98.05
• 1Y Price Target: $171.43
• Price Target Upside: 56.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 0.45
• Revenue Forecast (FY): $529.17M

• Rating: 59 Neutral
• Price Target: $141.00 ▲(29.03% Upside)

The score is driven by improving fundamentals and a strong, guidance-raising earnings narrative, supported by a solid balance sheet. These positives are materially offset by very stretched valuation (P/E ~2279.8) and mixed-to-weak near-term technical momentum (negative MACD; price below 20/50-day averages).

Positive Factors

Revenue Growth

The significant revenue growth of 52% YoY indicates strong demand for GeneDx's services, suggesting robust market expansion and increasing adoption of their genetic testing solutions.

FDA Breakthrough Designation

The FDA breakthrough designation validates GeneDx's technology as a leader in genetic testing, potentially enhancing its competitive position and driving future growth.

Improved Gross Margins

Improved gross margins to 74% reflect effective cost management and pricing strategies, enhancing profitability and financial health over the long term.

Negative Factors

Potential ASP Decline

Potential declines in ASPs could pressure future revenue growth and margins, affecting profitability if not offset by volume increases or cost reductions.

NICU Underpenetration

Significant underpenetration in the NICU market represents a missed opportunity for growth, indicating challenges in market expansion and adoption.

Discontinued Hereditary Cancer Offerings

Discontinuing hereditary cancer offerings may limit product diversity and revenue streams, potentially impacting the company's market position in genetic testing.

GeneDx Holdings Business Overview & Revenue Model

Company Description

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

How the Company Makes Money

GeneDx generates revenue primarily through the sale of its genetic testing services to healthcare providers, including hospitals, clinics, and genetic counselors. The company's revenue model is based on a fee-for-service structure, where clients pay for each genetic test conducted. Key revenue streams include whole genome sequencing tests, targeted gene panels, and consultation services that accompany the testing. Additionally, GeneDx may benefit from collaborations and partnerships with pharmaceutical companies and research institutions, which can provide funding for research initiatives and expand their testing capabilities. The company also engages in billing insurance providers, which can lead to reimbursement for services rendered, further contributing to its earnings.

GeneDx Holdings Financial Statement Overview

Summary

GeneDx Holdings has shown significant improvement in its income statement metrics over the TTM period. The gross profit margin improved to 69.65%, indicating strong cost management and pricing strategies. The net profit margin turned positive at 0.52%, a notable recovery from previous losses. Revenue growth rate is robust at 11.00%, reflecting successful business expansion. However, EBIT and EBITDA margins remain relatively low at 3.77% and 5.33%, respectively, suggesting room for operational efficiency improvements.

Income Statement

GeneDx Holdings has shown significant improvement in its income statement metrics over the TTM period. The gross profit margin improved to 69.65%, indicating strong cost management and pricing strategies. The net profit margin turned positive at 0.52%, a notable recovery from previous losses. Revenue growth rate is robust at 11.00%, reflecting successful business expansion. However, EBIT and EBITDA margins remain relatively low at 3.77% and 5.33%, respectively, suggesting room for operational efficiency improvements.

Balance Sheet

The balance sheet of GeneDx Holdings is stable with a debt-to-equity ratio of 0.21, indicating conservative leverage. The return on equity (ROE) is modest at 0.78%, reflecting the early stages of profitability. The equity ratio stands at 59.18%, showing a strong equity base relative to total assets. Overall, the balance sheet reflects a solid financial position with manageable debt levels.

Cash Flow

GeneDx Holdings has demonstrated impressive growth in free cash flow, with a 166.21% increase in the TTM period, indicating improved cash generation capabilities. The operating cash flow to net income ratio is 0.25, suggesting that cash flow from operations is still catching up with net income. The free cash flow to net income ratio of 0.70 indicates a healthy conversion of profits into cash, although there is room for further improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	402.19M	305.45M	202.57M	234.69M	212.19M	179.32M
Gross Profit	280.11M	194.40M	90.01M	-26.75M	-16.60M	4.03M
EBITDA	31.82M	-1.26M	-136.46M	-398.20M	-220.75M	-227.13M
Net Income	2.08M	-52.29M	-175.77M	-548.98M	-245.39M	-241.34M
Balance Sheet
Total Assets	493.90M	419.38M	418.76M	545.26M	554.09M	251.64M
Cash, Cash Equivalents and Short-Term Investments	155.08M	141.19M	130.15M	137.40M	400.57M	108.13M
Total Debt	113.16M	116.17M	119.77M	77.13M	32.85M	43.26M
Total Liabilities	201.64M	174.13M	190.74M	291.56M	165.99M	247.25M
Stockholders Equity	292.26M	245.25M	228.02M	253.71M	388.10M	4.39M
Cash Flow
Free Cash Flow	15.47M	-33.99M	-185.86M	-333.48M	-211.22M	-125.10M
Operating Cash Flow	33.19M	-28.50M	-180.15M	-319.15M	-190.43M	-93.13M
Investing Cash Flow	-50.96M	-30.13M	-43.73M	-141.33M	-20.79M	-31.97M
Financing Cash Flow	55.85M	44.16M	186.24M	197.31M	493.73M	129.06M

GeneDx Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 109.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WGS, the sentiment is Negative. The current price of 109.28 is below the 20-day moving average (MA) of 129.87, below the 50-day MA of 140.91, and below the 200-day MA of 109.38, indicating a bearish trend. The MACD of -8.13 indicates Positive momentum. The RSI at 28.94 is Positive, neither overbought nor oversold. The STOCH value of 8.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WGS.

GeneDx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTSG	67 Neutral	$6.93B	66.11	4.25%	―	17.23%	―
CERT	62 Neutral	$1.48B	141.25	1.03%	―	11.47%	―
TXG	60 Neutral	$2.65B	―	-10.12%	―	1.92%	59.18%
WGS	59 Neutral	$3.02B	1,812.27	0.84%	―	50.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SOPH	51 Neutral	$349.41M	-4.62	-86.09%	―	13.66%	-2.65%
EVH	48 Neutral	$435.24M	-2.51	-13.63%	―	-16.65%	-71.92%

GeneDx Holdings Corporate Events

GeneDx Reports Strong 2025 Results and 2026 Growth Outlook

On January 12, 2026, GeneDx reported preliminary, unaudited 2025 results showing revenues of about $427 million, up 41% year over year, driven by approximately $360 million in exome and genome revenue, which rose 54%, and test volumes that grew more than 30% to 97,271. Fourth quarter 2025 revenues were approximately $121 million, with exome and genome revenues of about $104 million and volume growth accelerating to 34.3%, while GAAP and adjusted gross margins held at about 70% and 71%, respectively, and year-end cash and investments totaled roughly $172 million. Management also issued 2026 guidance calling for revenue between $540 million and $555 million, exome and genome revenue and volume growth of 33% to 35%, adjusted gross margin of at least 70%, and positive adjusted net income, underscoring expectations of continued high growth and improving profitability. Alongside these figures, GeneDx highlighted strategic moves in 2025, including launching its GeneDx Infinity rare disease dataset, expanding into general pediatrics, prenatal diagnostics, and ultra-rapid sequencing, securing broader Medicaid coverage, completing leadership appointments, acquiring Fabric Genomics, and gaining FDA Breakthrough Device designation for key exome and genome tests, all of which reinforce its positioning as a leading player in genomic medicine and newborn screening.

The most recent analyst rating on (WGS) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on GeneDx Holdings stock, see the WGS Stock Forecast page.